Explore

Reuters Reuters
Novo outlook hike falls flat as Wegovy pill sales fail to impress

Novo outlook hike falls flat as Wegovy pill sales fail to impress

By Stine Jacobsen, Maggie Fick and Bhanvi Satija COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk raised its full-year profit and sales outlook on Tuesday but disappointed investors who focused instead on a narrow sales miss for its new Wegovy pill and a trial setback for its next-generation obesity drug
Trendline Trendline
Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance
Trendline Trendline
Merck Adjusts Revenue and Profit Outlook Amid Acquisition Charges

Merck Adjusts Revenue and Profit Outlook Amid Acquisition Charges

Merck Adjusts Revenue and Profit Outlook Amid Acquisition Charges
Reuters Reuters
Novo outlook hike falls flat as high Wegovy pill hopes unmet

Novo outlook hike falls flat as high Wegovy pill hopes unmet

By Stine Jacobsen and Maggie Fick COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk beat second-quarter profit forecasts and raised its full-year outlook on Wednesday, but shares in the drugmaker fell 6% as investors focused on underwhelming sales of its Wegovy weight-loss pill.
Trendline Trendline
Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology

Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology

Pathos AI Secures Global Licensing for JSKN016 from Alphamab Oncology
Trendline Trendline
Novo Nordisk Raises 2026 Forecasts Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Forecasts Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Forecasts Amid Strong GLP-1 Sales
Trendline Trendline
AbbVie's Revenue Growth Heavily Dependent on SKYRIZI Amidst Declining HUMIRA Sales

AbbVie's Revenue Growth Heavily Dependent on SKYRIZI Amidst Declining HUMIRA Sales

AbbVie's Revenue Growth Heavily Dependent on SKYRIZI Amidst Declining HUMIRA Sales
Trendline Trendline
SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report
TheStreet TheStreet
Novo Nordisk shares in hot water after disappointing trial

Novo Nordisk shares in hot water after disappointing trial

Investors who had hopes that Novo Nordisk (NVO) could succeed outside of weight-loss drugs were disappointed on Friday, July 31. The Danish drugmaker said its experimental heart drug Ziltivekimab failed the main goal of a large late-stage trial, and the stock fell fast. Novo has spent 2026 trying ...
TheStreet TheStreet
Morgan Stanley uncovers major Bristol Myers stock signals

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Trendline Trendline
AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns